- Home
- CRDF vs SRG Comparison
CRDF vs SRG Comparison
Compare CRDF & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- SRG
- Stock Information
- Founded
- CRDF 1999
- SRG 2014
- Country
- CRDF United States
- SRG United States
- Employees
- CRDF N/A
- SRG N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- SRG Real Estate Investment Trusts
- Sector
- CRDF Health Care
- SRG Real Estate
- Exchange
- CRDF Nasdaq
- SRG Nasdaq
- Market Cap
- CRDF 195.6M
- SRG 218.9M
- IPO Year
- CRDF N/A
- SRG 2015
- Fundamental
- Price
- CRDF $2.85
- SRG $2.89
- Analyst Decision
- CRDF Strong Buy
- SRG
- Analyst Count
- CRDF 4
- SRG 0
- Target Price
- CRDF $12.00
- SRG N/A
- AVG Volume (30 Days)
- CRDF 1.6M
- SRG 417.3K
- Earning Date
- CRDF 05-01-2025
- SRG 05-09-2025
- Dividend Yield
- CRDF N/A
- SRG N/A
- EPS Growth
- CRDF N/A
- SRG N/A
- EPS
- CRDF N/A
- SRG N/A
- Revenue
- CRDF $683,000.00
- SRG $14,568,000.00
- Revenue This Year
- CRDF N/A
- SRG N/A
- Revenue Next Year
- CRDF N/A
- SRG N/A
- P/E Ratio
- CRDF N/A
- SRG N/A
- Revenue Growth
- CRDF 39.96
- SRG N/A
- 52 Week Low
- CRDF $2.01
- SRG $2.43
- 52 Week High
- CRDF $5.64
- SRG $9.54
- Technical
- Relative Strength Index (RSI)
- CRDF 41.85
- SRG 44.82
- Support Level
- CRDF $2.36
- SRG $2.51
- Resistance Level
- CRDF $3.04
- SRG $2.84
- Average True Range (ATR)
- CRDF 0.24
- SRG 0.22
- MACD
- CRDF 0.03
- SRG 0.02
- Stochastic Oscillator
- CRDF 56.98
- SRG 51.11
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management and leasing of diversified and mixed-use properties throughout the United States.